LOGO
LOGO

Will Clinuvel Pharma Stock Pick Up Steam With Photoprotective Drug Advances?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

Erythropoietic protoporphyria is a genetic condition where protoporphyrins accumulate in red blood cells. This accumulation causes severe sensitivity to sunlight, resulting in acute pain, though without blistering. Additionally, there's a risk of liver disease associated with this condition. Symptoms typically begin in childhood, marked by immediate pain and crying upon exposure to bright sunlight. EPP tends to worsen during spring and summer months.

The stock we are bringing to your attention today is that of Australia-based Clinuvel Pharmaceuticals Limited (CLVLY.OB), which has an approved photoprotective drug.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.